Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Recruiting · NCT07180056 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged ≥18 and older
- Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
- HR+/HER2-
- ECOG 0-3
- Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
Exclusion criteria
- During pregnancy or lactation
- Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiaotong University - Shanghai, China